19 May Cytotheryx

Cytotheryx is a preclinical cell therapy company focused on the development of a consistent, high-quality source of human hepatocytes and the application of those cells for multiple research and clinical applications. Primary human hepatocytes are currently used in toxicology studies, hepatitis research, and transplants, but the limited supply restricts broader applications. Our foundational science will enable applications in liver assist devices, cell and gene therapy, drug delivery, and allotransplantation. Our initial target markets will focus on the unregulated use of the cells and include pharmaceutical companies, biotech companies, contract research organizations (CROs), and academic research institutions. Mayo Clinic holds the patent for the FRG pig, which serves as a bioincubator for the development of the liver cells. Cytotheryx has the exclusive license to this patent for commercialization. www.cytotheryx.com